Physician profile
Jeffrey Jacobs
NPI 1174524136
$12,911.84
in general payments reported to CMS, 2019-2025
42 companies · $3,424 in 2025
The $3,424 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $305 · 2021: $2,326 · 2022: $1,223 · 2023: $2,199 · 2024: $2,400 · 2025: $3,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,060 · Consulting Fee: $850 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,059.86 |
| Consulting Fee | $850.00 |
| Education | $114.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,822.91 | 2019-2025 | |
| Redhill Biopharma INC. | $1,753.53 | 2021-2024 | Talicia |
| Takeda Pharmaceuticals U.S.A., INC. | $1,430.80 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $1,283.57 | 2019-2025 | Tremfya, Stelara |
| Olympus Medical Systems Corporation | $850.00 | 2025 | Evis Exera III Duodenovideoscope |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $808.52 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Intercept Pharmaceuticals, INC. | $509.67 | 2019-2025 | Ocaliva |
| Pfizer INC. | $500.86 | 2019-2025 | |
| Celgene Corporation | $431.39 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $390.92 | 2019-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $345.60 | 2019-2025 | Sutab, Suflave |
| Lilly USA, LLC | $324.11 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $317.68 | 2022-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $276.34 | 2024-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $226.99 | 2019-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $190.17 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $148.78 | 2019-2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $147.02 | 2023 | |
| Genzyme Corporation | $105.80 | 2022-2023 | |
| Madrigal Pharmaceuticals | $105.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $99.48 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $90.94 | 2023 | Rebyota |
| Daiichi Sankyo INC. | $89.23 | 2021-2025 | Injectafer |
| Ironwood Pharmaceuticals, INC | $80.69 | 2019-2024 | Linzess |
| Allergan, INC. | $80.37 | 2019-2020 | |
| Ucb, INC. | $74.04 | 2019-2020 | |
| Celltrion USA INC. | $58.63 | 2024-2025 | Vegzelma, Zymfentra |
| Exact Sciences Corporation | $45.84 | 2023-2024 | Cologuard Collection Kit |
| Csl Behring | $40.75 | 2022-2023 | Kcentra |
| Sandoz INC. | $37.85 | 2023-2024 | Hyrimoz |
| Amgen INC. | $34.70 | 2021-2022 | |
| Axonics, INC. | $33.98 | 2022 | |
| Fresenius Kabi USA, LLC | $30.39 | 2023 | |
| Echosens North America, INC. | $25.14 | 2024 | Fibroscan |
| Nestle Healthcare Nutrition INC. | $24.04 | 2023 | |
| Organon LLC | $22.80 | 2023 | Renflexis, Hadlima |
| Micro-Tech Endoscopy USA, INC. | $18.24 | 2021 | |
| Ethicon US, LLC | $14.66 | 2019 | |
| W. L. Gore & Associates, INC. | $14.09 | 2021 | |
| Mauna Kea Technologies, INC. | $13.25 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.48 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$42,201.15 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.